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Conclusions: Successful CA of AF lowers the risk of stroke
and death.  
Perspective: The AFFIRM study showed that maintenance
of sinus rhythm was independently associated with reduced
mortality, but that this effect was neutralized by the delete-
rious effects of antiarrhythmic drug therapy. Given the
limitations of registry data and historical controls, the con-
clusions of this study are tentative, but the results suggest
that maintenance of sinus rhythm without need for antiar-
rhythmic drug therapy can improve outcomes.
Summary written by: Fred Morady, MD
Subclinical Atrial Fibrillation and the Risk of Stroke
Healey JS, Connolly SJ, Gold MR, at al.
N Engl J Med 2012;366:120-129.
Study Question: Do asymptomatic episodes of atrial tachy-
arrhythmia (AT) detected by a pacemaker or implanted
cardioverter-defibrillator (ICD) increase the risk of stroke? 
Methods: The subjects were 2,580 patients who underwent
implantation of a pacemaker or ICD. The selection criteria
were age ≥65 years (mean age 76 years), hypertension, and
no history of atrial fibrillation (AF). A subclinical AT was
defined as an asymptomatic atrial high-rate event >190 bpm
lasting >6 minutes. Patients in whom ATs were noted at 3
months of follow-up were randomly assigned to receive or
not receive continuous atrial overdrive pacing. The primary
outcome was ischemic stroke or systemic embolism.
Results: Subclinical ATs (median two/patient, mean rate 480
bpm) were noted in 10.1% of patients at 3 months of fol-
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Arrhythmias
Maintenance of Sinus Rhythm With an Ablation
Strategy in Patients With Atrial Fibrillation Is
Associated With a Lower Risk of Stroke and Death
Hunter RJ, McCready J, Diab I, et al.
Circ Arrhythm Electrophysiol 2011;Dec 7:[Epub ahead of print].
Study Question: Does catheter ablation (CA) of atrial fibrilla-
tion (AF) improve long-term outcomes? 
Methods: CA of AF (paroxysmal in 56%) was performed in
1,273 patients (mean age 58 years) enrolled in an ablation
registry. Success was defined as freedom from AF/tachycar-
dia after a 3-month blanking period. The rates of stroke and
death were compared between patients with and without
recurrent AF, and patients who underwent CA and a cohort
with medically-treated AF. Outcomes also were compared
with a hypothetical age/gender-matched group in the gen-
eral population, based on United Kingdom national
statistics.  
Results: The procedural major complication rate was 5.4%.
The mean duration of follow-up after a mean of 1.8 proce-
dures was 2.2 years. Freedom from AF was achieved in 85%
of patients with paroxysmal AF and 72% with persistent
AF. Freedom from AF was independently associated with a
70% reduction in stroke/mortality. The annual stroke/mor-
tality rates (0.5% for each) were significantly lower in the
CA patients than in the medically-treated cohort (2.8% and
5.3%, respectively), and similar to the stroke/mortality rates
in the general population (0.4% and 1.0%, respectively). 
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Conclusions: Marathons and half-marathons are associated
with a low overall risk of cardiac arrest and sudden death.
Cardiac arrest, most commonly attributable to hypertrophic
cardiomyopathy or atherosclerotic coronary disease, occurs
primarily among male marathon participants; the incidence
rate in this group increased during the past decade. 
Perspective: I run marathons. If I die during a marathon, I am
OK with it. This study does an excellent job in demonstrat-
ing that cardiovascular death occurs during distance races,
but that it is rare. Exercise has dramatic physical and mental
benefits. Even if it does not confer immortality, physicians
should emphasize the benefits of exercise rather than perse-
verating on the rare cardiac death that happens to occur
during an athletic event.
Summary written by: David S. Bach, MD
Cardiovascular Surgery
Bridging Antiplatelet Therapy With Cangrelor in
Patients Undergoing Cardiac Surgery:
A Randomized Controlled Trial
Angiolillo DJ, Firstenberg MS, Price MJ, et al., on behalf of the
BRIDGE Investigators.
JAMA 2012;307:265-274.
Study Question: What is the effect of cangrelor, an intravenous,
reversible P2Y12 platelet inhibitor, for bridging thienopyri-
dine-treated patients to coronary artery bypass grafting
(CABG) surgery?
Methods: BRIDGE was a prospective, randomized, double-
blind, placebo-controlled, multicenter trial, involving 210
patients with an acute coronary syndrome or treated with a
coronary stent and receiving a thienopyridine awaiting
CABG surgery to receive either cangrelor or placebo after an
initial open-label, dose-finding phase (n = 11) conducted
between January 2009 and April 2011. Thienopyridines were
stopped and patients were administered cangrelor or placebo
for at least 48 hours, which was discontinued 1-6 hours
before CABG surgery. The primary efficacy endpoint was
platelet reactivity (measured in P2Y12 reaction units
[PRUs]), assessed daily. The main safety endpoint was
excessive CABG surgery–related bleeding. The primary effi-
cacy endpoint, the percentage of patients who maintained a
PRU <240 during study drug infusion prior to surgery, was
analyzed.
Results: The dose of cangrelor determined in 10 patients in
the open-label stage was 0.75 μg/kg per minute. In the ran-
domized phase, a greater proportion of patients treated with
cangrelor had low levels of platelet reactivity through the
entire treatment compared with placebo (primary endpoint,
PRU <240; 98.8% vs. 19.0%; relative risk [RR], 5.2; p <
0.001). Excessive CABG surgery–related bleeding occurred
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low-up. During the entire follow-up, subclinical ATs were
noted in 34.6% of patients and clinical AF occurred in
15.7% of patients. During a mean of 2.5 years of follow-up,
the annual risk of stroke/embolism was significantly higher
in patients with than without a subclinical AT detected at 3
months (1.7% vs. 0.7%, hazard ratio [HR], 2.5). During
follow-up, AT episodes >6 minutes, >6 hours, and >24
hours were associated with a similar degree of increased risk
of stroke/embolism (HRs 1.8, 2.0, and 2.0, respectively).
Continuous atrial overdrive pacing did not prevent ATs. 
Conclusions: Asymptomatic AF detected by cardiac devices is
associated with an increased risk of stroke/embolism.
Perspective: Because only AT episodes longer than 6 minutes
were included in the analysis, the minimum duration of sub-
clinical ATs associated with thromboembolic complications is
unclear. Whether anticoagulation has a net benefit in patients
with subclinical ATs also remains to be determined.
Summary written by: Fred Morady, MD
Cardiac Arrest During Long-Distance Running
Races
Kim JH, Malhotra R, Chiampas G, et al., on behalf of the Race
Associated Cardiac Arrest Event Registry (RACER) Study Group
N Engl J Med 2012;366:130-140.
Study Question: What are the incidence and outcomes of car-
diac arrest associated with marathon and half-marathon
races in the United States?
Methods: The incidence and outcomes of cardiac arrest asso-
ciated with marathon and half-marathon races in the United
States were assessed from January 1, 2000, to May 31, 2010.
The clinical characteristics of the arrests were determined by
interviewing survivors and next of kin of nonsurvivors,
reviewing medical records, and analyzing postmortem data.
Results: Of 10.9 million runners, 59 (mean [± standard devi-
ation] age 42 ± 13 years; 51 men) had cardiac arrest
(incidence rate 0.54 per 100,000 participants).
Cardiovascular disease accounted for the majority of cardiac
arrests. The incidence rate was significantly higher during
marathons (1.01 per 100,000) than during half-marathons
(0.27), and among men (0.90 per 100,000) than among
women (0.16). Male marathon runners, the highest-risk
group, had an increased incidence of cardiac arrest during
the latter half of the study decade (2000-2004, 0.71 per
100,000; 2005-2010, 2.03 per 100,000; p = 0.01). Of the 59
cases of cardiac arrest, 42 were fatal (incidence, 0.39 per
100,000). Among the 31 cases with complete clinical data,
initiation of bystander-administered cardiopulmonary resus-
citation and an underlying diagnosis other than
hypertrophic cardiomyopathy were the strongest predictors
of survival.
0.87). Postoperative moderate-to-severe TR was an independ-
ent predictor of poorer event-free survival (HR, 2.90; p =
0.038).  
Conclusions: The findings support a strategy of correcting mild-
to-moderate functional TR at the time of MVR to maintain
tricuspid valve function and improve clinical outcomes. 
Perspective: This study does a nice job of showing that patients
who underwent mechanical MVR had less TR on follow-up if
concomitant tricuspid annuloplasty was performed. However,
measured clinical endpoints did not appear to differ between
groups, and it remains an act of faith that tricuspid annulo-
plasty results in less postoperative right-sided heart failure
after otherwise successful MV surgery.
Summary written by: David S. Bach, MD
Clinical Outcomes in Non-Surgically Managed
Patients With Very Severe Versus Severe Aortic
Stenosis
Kitai T, Honda S, Okada Y, et al.
Heart 2011;97:2029-2032.
Study Question: What are the clinical outcomes of patients
with severe versus very severe aortic stenosis (AS)?  
Methods. In a single-center, retrospective cohort study, 108
conservatively treated patients with severe AS (maximal jet
velocity ≥4.0 m/s, mean aortic pressure gradient [MPG] ≥40
mm Hg, or aortic valve area [AVA] <1.0 cm2) and 58
patients with very severe AS (maximal jet velocity ≥5.0 m/s,
MPG ≥50 mm Hg, or AVA <0.6 cm2) were compared.
Clinical outcomes (all-cause mortality and valve-related
events [defined by a composite of cardiac death and hospi-
talization because of heart failure]) were assessed. 
Results. Mean follow-up was 5.5 ± 3.1 years. A total of 56
patients (52%) with severe AS and 20 patients (34%) with
very severe AS were asymptomatic. At 3 years, very severe
AS patients had poorer survival and valve-related event-free
survival than did severe AS patients (77% vs. 88%, p < 0.01;
75% vs. 88%, p < 0.001, respectively). The 3-year survival
and valve-related event-free survival of asymptomatic very
severe AS were comparable with symptomatic severe AS,
but were significantly worse than asymptomatic severe AS
patients (p < 0.01 and p < 0.001, respectively). 
Conclusions. Surgery should always be considered in patients
with very severe AS regardless of symptoms, and particular
attention needs to be paid to their extremely poor outcomes.
Perspective. The dogma that all patients with severe AS are at
low risk as long as they remain asymptomatic needs to be
reassessed. This study does a nice job of demonstrating that
in 11.8% versus 10.4% in the cangrelor and placebo groups,
respectively (RR, 1.1; p = 0.763). There were no significant
differences in major bleeding prior to CABG surgery,
although minor bleeding episodes were numerically higher
with cangrelor.
Conclusions: Among patients who discontinue thienopyridine
therapy prior to cardiac surgery, the use of cangrelor com-
pared with placebo resulted in a higher rate of maintenance
of platelet inhibition.
Perspective: This study suggests that cangrelor infusion consis-
tently achieved and maintained platelet inhibition at levels
known to be associated with a low risk of thrombotic events
compared with placebo. Furthermore, bridging with a pro-
longed infusion of cangrelor did not increase major bleeding
prior to surgery, although minor bleeding was higher. Thus,
intravenous cangrelor appears to be a feasible management
strategy in patients waiting for cardiac surgery who require
prolonged platelet P2Y12 inhibition after thienopyridine dis-
continuation.
Summary written by: Debabrata Mukherjee, MD
Mild-to-Moderate Functional Tricuspid
Regurgitation in Patients Undergoing Valve
Replacement for Rheumatic Mitral Disease: The
Influence of Tricuspid Valve Repair on Clinical and
Echocardiographic Outcomes
Kim JB, Yoo DG, Kim GS, et al.
Heart 2012;98:24-30.
Study Question: Should concomitant tricuspid valve repair be
performed among patients with mild-to-moderate functional
tricuspid regurgitation (TR) undergoing mitral valve surgery?
Methods: Between 1997 and 2009, 236 patients with mild-to-
moderate functional TR underwent first-time isolated
mechanical MVR for rheumatic mitral disease. Of these, 123
underwent concomitant tricuspid valve repair (repair group)
and 113 did not (nonrepair group). Survival, valve-related
complications, and tricuspid valve function in the two groups
were compared after adjustment for baseline characteristics
using inverse-probability-of-treatment weighting.
Results: Follow-up was complete in 225 patients (95.3%), with
a median follow-up of 48.7 months. During that time, 991
echocardiographic assessments were done. Freedom from
moderate-to-severe TR at 5 years was 92.9 ± 2.9% in the
repair group and 60.8 ± 6.9% in the nonrepair group (p <
0.001 and 0.048 in crude and adjusted analyses, respectively).
After adjustment, both groups had similar risks of death (haz-
ard ratio [HR], 0.57; p = 0.43), tricuspid reoperation (HR,
0.10; p = 0.080), and congestive heart failure (HR, 1.12; p =
JACC Vol. 59, No. 10, 2012
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not all ‘severe’ AS is the same. Patients with very severe AS
were at high risk for morbid and mortal valve-related
events. In patients with severe AS, lack of symptoms should
not be taken as an over-riding reason to discount considera-
tion for surgical intervention. 
Summary written by: David S. Bach, MD
Heart Valve Prosthesis Selection in Patients With
End-Stage Renal Disease Requiring Dialysis:
A Systematic Review and Meta-Analysis
Chan V, Chen L, Mesana L, Mesana TG, Ruel M.
Heart 2011;97:2033-2037.
Study Question: Are there clinical data to support the use of a
bioprosthesis versus a mechanical prosthesis among patients
with end-stage renal disease (ESRD) on hemodialysis who
undergo heart valve replacement?
Methods: A meta-analysis was performed using studies pub-
lished in English beginning in 1990 if they compared
bioprostheses with mechanical prostheses in patients with
ESRD on dialysis. Extracted summary estimates included
the hazard ratio (HR) for death and odds ratio (OR) for
developing valve-related complications due to use of bio-
prostheses versus mechanical prostheses.
Results: Twelve studies published from 1997 to 2010 were
included in this review, of which nine were used in the
meta-analysis. In these studies, the aortic valve was the most
common valve replaced (4,339 of 6,350), although 11 of the
12 studies also included mitral or multiple valve replace-
ments. No difference in survival was observed between valve
types (bioprosthesis vs. mechanical prosthesis, HR, 1.3; p =
0.09). However, valve replacement with a bioprosthesis was
associated with fewer valve-related complications compared
to a mechanical prosthesis (OR, 0.4; p = 0.002). 
Conclusions: A meta-analysis of the published literature
demonstrated no survival difference following valve replace-
ment with either a bioprosthesis or mechanical prosthesis in
patients with ESRD on dialysis. Bioprosthetic valve replace-
ment was associated with fewer valve-related complications.
The authors concluded that the data can likely be extended to
include at least aortic valve replacement.
Perspective: This meta-analysis confirms that fears of higher
mortality after bioprosthetic valve replacement are unfounded.
Avoiding long-term Coumadin therapy among patients who
typically require three-times weekly vascular access for
hemodialysis likely contributes to fewer valve-related compli-
cations in association with a bioprosthesis.
Summary written by: David S. Bach, MD
General
CYP2C19 Genotype, Clopidogrel Metabolism,
Platelet Function, and Cardiovascular Events:
A Systematic Review and Meta-Analysis 
Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP.
JAMA 2011;306:2704-2714.
Study Question: What is the evidence on the association of
CYP2C19 genotype and clopidogrel response?
Methods: Studies that reported clopidogrel metabolism,
platelet reactivity, or clinically relevant outcomes (cardiovas-
cular disease [CVD] events and bleeding), and information
on CYP2C19 genotype were included. The investigators
extracted information on study design, genotyping, and dis-
ease outcomes, and investigated sources of bias. They
estimated absolute risk differences between genotype cate-
gories based on the control group event rate from the CURE
(acute coronary syndrome) and CHARISMA (stable coro-
nary heart disease) trials and the trim-and-fill summary
relative risk (RR) (to minimize small-study bias), comparing
carriers of any loss-of-function CYP2C19 allele versus the
reference category, and assuming consistency of RRs across a
range of baseline absolute risks of cardiovascular and bleed-
ing events. 
Results: The authors retrieved 32 studies of 42,016 patients
reporting 3,545 CVD events, 579 stent thromboses, and
1,413 bleeding events. Six studies were randomized trials
(“effect-modification” design) and the remaining 26 reported
individuals exposed to clopidogrel (“treatment-only” design).
In treatment-only analysis, individuals with one or more
CYP2C19 alleles associated with lower enzyme activity had
lower levels of active clopidogrel metabolites, less platelet
inhibition, lower risk of bleeding (RR, 0.84; absolute risk
reduction of 5-8 events per 1,000 individuals), and higher
risk of CVD events (RR, 1.18; absolute risk increase of 8-12
events per 1,000 individuals). However, there was evidence
of small-study bias. When analyses were restricted to studies
with 200 or more events, the point estimate was attenuated
(RR, 0.97). In effect-modification studies, CYP2C19 geno-
type was not associated with modification of the effect of
clopidogrel on CVD endpoints or bleeding (p > 0.05 for
interaction for both). 
Conclusions: Although there was an association between the
CYP2C19 genotype and clopidogrel responsiveness, overall
there was no significant association of genotype with CV
events.
Perspective: This systematic review and meta-analysis does
not demonstrate a clinically important association of
CYP2C19 genotype with CV outcomes with the possible
exception of stent thrombosis. A large randomized controlled
trial is needed to adequately test the clopidogrel pharma-
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International Variation in and Factors Associated
With Hospital Readmission After Myocardial
Infarction
Kociol RD, Lopes RD, Clare R, et al.
JAMA 2012;307:66-74.
Study Question: What is the international variation in readmis-
sion rates among patients treated with primary percutaneous
coronary intervention (PCI) for ST-segment elevation
myocardial infarction (STEMI)? 
Methods: The authors retrospectively evaluated the country
level variation in readmission among 5,745 patients with
STEMI enrolled in the Assessment of Pexelizumab in Acute
Myocardial Infarction trial. This trial enrolled 5,745 patients
with STEMI at 296 sites in the United States, Canada,
Australia, New Zealand, and 13 European countries.
Multivariable logistic regression analysis was used to identify
independent predictors of all-cause and nonelective 30-day
post-discharge readmission.
Results: Of the 5,571 patients discharged alive, 11.3% were
readmitted within 30 days. US patients had higher 30-day
readmission rates (14.5% vs. 9.9%). Median length of stay
was shortest for US patients (3 days) and longest in patients
from Germany (8 days). The predictors of all-cause 30-day
readmission included multivessel disease (odds ratio [OR],
1.97) and US location (OR, 1.68), but multivessel disease
was not significant when admission for elective revascular-
ization was excluded. Enrollment in the US was, however,
an independent predictor of readmission (OR, 1.53) after
excluding elective readmissions for revascularization. After
adjustment for country-level median length of stay, US loca-
tion was no longer an independent predictor of 30-day
all-cause or nonelective readmission. There was an inverse
relation between country-level median length of stay and
readmission, with a 14% reduction in the odds of readmis-
sion for each additional in-hospital day (OR, 0.86). There
was no impact of US enrollment on in-hospital death (OR,
0.88) or 30-day post-admission death (OR, 1.0). 
Conclusions: There was significant variation in the rate of read-
mission among patients with STEMI, with the US having the
highest rates of readmission.  
Perspective: There is increasing interest in readmission after
hospitalization after STEMI as a quality and an economic
measure. This study demonstrates a marked variation in
readmission rates across the participating countries without
differences in mortality. The higher rate of readmission in
the US is counterbalanced by short length of stay, and
efforts to reduce readmission may come at the cost of pro-
longing hospitalization. Further studies are warranted to
define patient-level predictors of readmission so that focused
interventions can be targeted to reduce readmission rates.
Summary written by: Hitinder S. Gurm, MBB 
cogenomic hypothesis and its clinical significance. Pending
such a study, physicians should use CYP2C19 or platelet
reactivity testing rarely, if ever, and interpret the results with
appropriate caution.
Summary written by: Debabrata Mukherjee, MD
Serum Potassium Levels and Mortality in Acute
Myocardial Infarction
Goyal A, Spertus JA, Gosch K, et al.
JAMA 2012;307:157-164.
Study Question: What is the association between average
serum potassium during hospitalization and the outcome of
patients with acute myocardial infarction (AMI)?
Methods: The authors retrospectively evaluated the outcome
of 38,689 patients in the Cerner Health Facts database, who
were hospitalized with biomarker-confirmed AMI, to 67 US
hospitals from 2000-2008. All patients had in-hospital
serum potassium measurements and were categorized by
mean postadmission serum potassium level. Hierarchical
logistic regression was used to determine the association
between potassium levels and outcomes after adjusting for
patient- and hospital-level factors.
Results: A U-shaped relationship between mean postadmis-
sion serum potassium level and in-hospital mortality
persisted after multivariable adjustment for multiple factors.
The mortality among the reference group with potassium
(K) levels of 3.5-<4.0 mEq/L was 4.8%, and was similar in
those with postadmission potassium of 4.0-<4.5 mEq/L
(5.0%). Mortality increased with an increase in serum potas-
sium (K 4.5-<5.0 mEq/L, mortality 10.0%; K 5-<5.5
mEq/L, mortality 24.8%; K >5.5 mEq/L, mortality 61.4%).
A lesser degree of increase in mortality was observed with
decreasing average potassium levels (K <3 mEq/L, mortality
46.2%; K 3-<3.5 mEq/L, mortality 11.4). Rates of ventricu-
lar fibrillation or cardiac arrest were higher only among
patients with potassium levels of <3.0 mEq/L and at levels
of 5.0 mEq/L or greater.
Conclusions: Among patients hospitalized with AMI, the
lowest mortality was observed in those with postadmission
serum potassium levels between 3.5 and <4.5 mEq/L com-
pared with those who had higher or lower potassium levels.
Perspective: There was a disconnect between occurrence of
cardiac arrest or ventricular fibrillation and total mortality at
both extremes in this study; an increase was seen only with
extreme levels of serum potassium. This raises concern about
residual confounding and reverse causality, the elegant ana-
lytical design notwithstanding. Although prior guidelines are
based on a small body of observational data, it may be pre-
mature to change current practice without randomized data.
Summary written by: Hitinder S. Gurm, MBBS
JACC Vol. 59, No. 10, 2012
March 6, 2012:883-90
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Cardiovascular Mortality in Women With
Obstructive Sleep Apnea With or Without
Continuous Positive Airway Pressure Treatment:
A Cohort Study
Campos-Rodriguez F, Martinez-Garcia MA, de la Cruz-Moron I,
Almeida-Gonzalez C, Catalan-Serra P, Montserrat JM.
Ann Intern Med 2012;156:115-122.
Study Question: Is obstructive sleep apnea (OSA) a risk factor
for cardiovascular death in women, and does continuous
positive airway pressure (CPAP) treatment reduce mortality
risk? 
Methods: This was a prospective observational cohort study,
which enrolled women from two sleep clinics in Spain. All
women were referred for suspected OSA between 1998 and
2007, and received a diagnostic sleep study. Women with an
apnea–hypopnea index (AHI) less than 10 were the control
group. OSA was diagnosed when the AHI was 10 or higher
(classified as mild to moderate [AHI of 10-29] or severe
[AHI ≥30]). Women were classified as treated if they wore
their CPAP ≥4 hours per day, and untreated if CPAP was
worn <4 hours per day (or not prescribed). Participants were
followed until December 2009. The primary outcome was
cardiovascular mortality.
Results: A total of 1,116 women were included (median fol-
low-up, 72 months). The control group had a lower
cardiovascular mortality rate (0.28 per 100 person-years)
than the untreated groups with mild to moderate OSA
(0.94 per 100 person-years) or severe OSA (3.71 per 100
person-years). Compared with the control group, the fully
adjusted hazard ratios for cardiovascular mortality were 3.50
for the untreated, severe OSA group; 0.55 for the CPAP-
treated, severe OSA group; 1.60 for the untreated, mild to
moderate OSA group; and 0.19 for the CPAP-treated,
mild to moderate OSA group. 
Conclusions: Severe OSA is associated with increased risk of
cardiovascular death in women, and adequate CPAP treat-
ment may reduce this risk. 
Perspective: OSA is associated with both cardiovascular risk
factors and cardiovascular disease mortality in men. This
study suggests the risk of cardiovascular disease mortality
associated with OSA is also present in women. A random-
ized controlled trial examining treatment of OSA in
relation to cardiovascular disease risk among women would
be recommended, based on these findings.
Summary written by: Elizabeth A. Jackson, MD 
Long-Term Cardiovascular Mortality After
Procedure-Related or Spontaneous Myocardial
Infarction in Patients With Non-ST-Segment
Elevation Acute Coronary Syndrome:
A Collaborative Analysis of Individual Patient Data
From the FRISC II, ICTUS, and RITA-3 Trials (FIR)
Damman P, Wallentin L, Fox KA, et al.
Circulation 2011;Dec 23:[Epub ahead of print].
Study Question: What is the long-term prognostic impact of
procedure-related and spontaneous myocardial infarction
(MI) on cardiovascular mortality in patients with non-ST-
elevation acute coronary syndrome (NSTE-ACS)? 
Methods: Five-year follow-up after procedure-related or
spontaneous MI was investigated in the individual patient-
pooled data set of the FRISC-II, ICTUS, and RITA-3
(FIR) NSTE-ACS trials. The principal outcome was car-
diovascular death up to 5 years of follow-up. Cumulative
event rates were estimated with the Kaplan-Meier method,
and hazard ratios (HRs) were calculated with time-depen-
dent Cox proportional-hazards models. Adjustments were
made for variables associated with long-term outcomes. 
Results: Of the 5,467 patients, 212 endured a procedure-
related MI within 6 months after enrollment. A
spontaneous MI occurred in 236 patients within 6 months.
The cumulative cardiovascular death rate was 5.2% in
patients who endured a procedure-related MI and compara-
ble to patients without a procedure-related MI (HR, 0.66; p
= 0.17). In patients who endured a spontaneous MI within
6 months, the cumulative cardiovascular death rate was
22.2% and higher than patients without a spontaneous MI
(HR, 4.52; p < 0.001). These HRs did not materially alter
after risk adjustments. 
Conclusions: Five-year follow-up of NSTE-ACS patients from
the three trials showed no association between a procedure-
related MI and long-term cardiovascular mortality. 
Perspective: The study findings emphasize the importance of
differentiating effects on different types of MI when evalu-
ating the efficacy and safety of new medical and
interventional treatments and translating these findings for
treatment recommendations. The study also raises the ques-
tion of whether procedure-related MI is a valid outcome for
clinical trials.
Summary written by: Debabrata Mukherjee, MD
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Diffusion-Weighted MRI Determined Cerebral
Embolic Infarction Following Transcatheter Aortic
Valve Implantation: Assessment of Predictive Risk
Factors and the Relationship to Subsequent Health
Status
Fairbairn TA, Mather AN, Bijsterveld P, et al.
Heart 2012;98:18-23.
Study Question: What are the frequency and predictors of
cerebral infarction in patients undergoing transcatheter aor-
tic valve implantation (TAVI), and its impact on patient
health-related quality of life (HRQoL)?
Methods: The authors performed cerebral diffusion-weighted
MRI on 31 patients before and after CoreValve TAVI.
HRQoL was assessed at baseline and at 30 days by SF-12v2
and EQ5D questionnaires.
Results: New cerebral infarction on diffusion-weighted
imaging was seen in 24/31 patients (77%), and stroke in 2
patients (6%). There were 131 new infarcts distributed
equally between the cerebral hemispheres (left 53%, right
47%), and in multiple territories (anterior 7%, middle 59%,
posterior 14%, and vertebrobasilar 20%). The average num-
ber of infarcts per patient was 4.2 and the median was 2.
Stroke was associated with a greater number and volume of
cerebral infarcts. Age, severity of aortic atheroma, and
catheterization time were independent predictors of the
number of new cerebral infarcts. HRQoL as assessed by
SF-12v2 physical component summary increased signifi-
cantly (32.4 vs. 36.5), with no significant change in mental
component summary (43.56 vs. 43.16). The EQ5D score
(0.56 vs. 0.59) and Visual Analogue Scale (54.2 vs. 58.2)
showed no significant change.  
Conclusions: Among patients undergoing TAVI, silent cerebral
infarction is common and is associated with increased age and
severity of arch atheroma. 
Perspective: Stroke remains one of the most important com-
plications of TAVI. In this small study, silent cerebral
infarction was seen in most patients, and this, combined
with the relatively high frequency of clinical stroke observed
in other studies, invokes the need for evaluation of
embolization protection devices to improve procedural
safety.
Summary written by: Hitinder S. Gurm, MBB 
Prevention/Vascular
Bariatric Surgery and Long-Term Cardiovascular
Events
Sjöström L, Peltonen M, Jacobson P, et al.
JAMA 2012;307:56-65.
Study Question: Does bariatric surgery, resulting in weight
loss, reduce the risk of cardiovascular (CV) events? 
Methods: Data from the Swedish Obese Subjects (SOS)
study were used for this analysis. The SOS study is an
ongoing nonrandomized prospective study of 2,010 obese
subjects who underwent bariatric surgery and 2,037 contem-
poraneously matched obese controls who received usual care,
recruited between September 1, 1987, and January 31, 2001.
Inclusion criteria were ages 37-60 years and a body mass
index (BMI) of at least 34 in men and at least 38 in women.
The primary outcomes included myocardial infarction and
stroke. 
Results: At baseline, the mean BMI was 40.1 in the control
and 42.4 in the surgery group. The mean changes in body
weight after 2, 10, 15, and 20 years were −23%, −17%,
−16%, and −18% in the surgery and 0%, 1%, −1%, and −1%
in the control group. Surgery patients underwent gastric
bypass (13.2%), banding (18.7%), or vertical banded gastro-
plasty (68.1%), and controls received usual care in the
Swedish primary health care system. Over a median follow-
up of 14.7 years, bariatric surgery was associated with a
reduced number of CV deaths (28 events in the surgery vs.
49 in the control group; adjusted hazard ratio [HR], 0.47).
The number of total first time (fatal or nonfatal) CV events
(myocardial infarction or stroke) was lower in the surgery
group (199 events in the surgery vs. 234 in the control
group). Higher baseline insulin concentrations were associ-
ated with more favorable outcomes in bariatric surgery
patients. No significant interactions were noted between
BMI, or other metabolic and anthropometric variables,
bariatric surgery, and CV outcomes. 
Conclusions: Compared with usual care, bariatric surgery was
associated with a reduced number of CV deaths and lower
incidence of CV events in obese adults. 
Perspective: This study provides evidence that bariatric sur-
gery resulting in weight loss also lowers risk for CV
outcomes, although the study is limited by the lack of ran-
domization. Further research is need to fully understand
which patients benefit the most from such surgeries, and
what is key to CV risk modification.
Summary written by: Elizabeth A. Jackson, MD 
JACC Vol. 59, No. 10, 2012
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Increased Short-Term Risk of Thrombo-Embolism
or Death After Interruption of Warfarin Treatment in
Patients With Atrial Fibrillation
Raunso J, Selmer C, Olesen JB, et al.
Eur Heart J 2011;Dec 23:[Epub ahead of print]. 
Study Question: What is the risk and timing of thromboem-
bolic events associated with interruptions of warfarin
treatment in atrial fibrillation? 
Methods: This was a retrospective nationwide cohort study of
all patients in Denmark treated with warfarin for atrial fibril-
lation, using the Danish National Patient Registry. Analysis
included patients with nonvalvular atrial fibrillation, greater
than age 30, after a first hospitalization for atrial fibrillation
with subsequent use of warfarin. Warfarin use interruption
was assumed to start when a patient ran out of available war-
farin tablets, as calculated based on prescription claims.
Incident rate ratios (IRRs) were calculated using Poisson
regression for estimates of thromboembolic events and all-
cause mortality.  
Results: Between 1997 and 2008, 48,980 atrial fibrillation
patients were identified, of which 35,396 had one estimated
warfarin interruption, among whom there were 8,255 deaths
or thromboembolic events associated with treatment inter-
ruption. The timing of these events was clustered as follows:
2,717, 835, 500, and 427 events occurred during 0-90, 91-
180, 181-270, and 271-360 days after warfarin treatment
interruption, respectively. The corresponding crude incident
rates were 31.6, 17.7, 12.3, and 11.4 events per 100 patient-
years. By multivariable analysis, the initial 90-day interval
after treatment interruption was associated with a markedly
higher risk of death or thromboembolism (IRR, 2.5; 95%
confidence interval, 2.3-2.8) versus the interval between 271
and 360 days after warfarin treatment interruption.  
Conclusions: In patients with atrial fibrillation, an interruption
of warfarin treatment is associated with a significantly
increased short-term risk of death with thromboembolic
events within the first 90 days after treatment interruption. 
Perspective: The study does not evaluate elective interruptions
of therapy (e.g., surgical procedures), but rather identifies
warfarin treatment interruption by identifying periods of
time when supply of medication ran out. Furthermore, the
median duration of treatment interruptions was 36 days, sig-
nificantly exceeding the usual elective interruption for an
invasive procedure. In spite of these limitations, the data are
extremely useful, and suggest that the risk of thromboem-
bolism or death is more than doubled within 90 days after
warfarin treatment interruption for a median of 36 days.
Summary written by: James B. Froehlich, MD, MPH
Pharmacogenetic Determinants of Statin-Induced
Reductions in C-Reactive Protein
Chu AY, Giulianini F, Barratt BJ, Nyberg F, Chasman DI, Ridker PM.
Circ Cardiovasc Genet 2012;Jan 9:[Epub ahead of print]. 
Study Question: Do different mechanisms underlie statin-
induced C-reactive protein (CRP) and low-density
lipoprotein cholesterol (LDL-C) reduction?
Methods: This study evaluated potential genetic determinants
of CRP response using genome-wide genetic data from
6,766 participants of European ancestry randomly allocated
to 20 mg/day of rosuvastatin or placebo in the JUPITER
trial. 
Results: Among 3,386 rosuvastatin-allocated individuals, both
CRP and LDL-C levels were reduced by 50% after 12
months of therapy (both p values < 0.001) and essentially
uncorrelated (r2 < 0.03). None of the three genes (ABCG2,
LPA, and APOE) that previously showed genome-wide asso-
ciation with LDL-C reduction in this cohort and none of
the candidate single nucleotide polymorphisms (SNPs) asso-
ciated with LDL-C reduction were associated with
rosuvastatin-induced CRP change after multiple testing cor-
rection. Among candidate SNPs selected from prior genetic
analyses of baseline CRP, CRP reduction was associated
with rs2794520 in CRP (mean -3.5% change in CRP per
minor allele, p = 6.4 x 10–4), and with rs2847281 in PTPN2
(mean 3.7% change in CRP per minor allele, p = 7.4 x 10–4).
Neither variant was associated with rosuvastatin-induced
LDL-C reduction or with CRP reduction among 3,380
placebo-allocated JUPITER participants.
Conclusions: The genetic determinants of rosuvastatin-
induced CRP reduction differ from, and are largely
independent of, the major pharmacogenetic determinants of
rosuvastatin-induced LDL-C reduction. This supports the
hypothesis that differing pathways may mediate the anti-
inflammatory and lipid-lowering properties of statin therapy.  
Perspective: There is evidence that the reduction in cardiovas-
cular event rate in placebo-controlled primary and secondary
coronary heart disease prevention trials with atorvastatin,
pravastatin, and rosuvastatin is related to both magnitude of
reduction in LDL-C and achieving a high-sensitivity CRP
<1 mg/L. Based on this study, the degree to which different
statins influence the genetic determinants of CRP and
immune function may impact their clinical efficacy inde-
pendent of lipid-lowering effect, a posit not accepted by
many.
Summary written by: Melvyn Rubenfire, MD
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